Anti-IL-2 Receptor Antibodies versus Anti-Thymocyte Globulin for Induction Therapy in Kidney Transplantation

被引：7
作者：
Mandelbrot, Didier [1 ]
机构：
[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Transplant Inst, Boston, MA 02215 USA
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2009年 / 20卷 / 06期
关键词：
RABBIT ANTITHYMOCYTE GLOBULIN; RENAL-ALLOGRAFT RECIPIENTS; CONTAINING TRIPLE THERAPY; ACUTE CELLULAR REJECTION; MYCOPHENOLATE-MOFETIL; BASILIXIMAB INDUCTION; MONOCLONAL-ANTIBODY; IMMUNOPROPHYLAXIS; EFFICACY;
D O I：
10.1681/ASN.2009040389
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1170 / 1171
页数：2
相关论文
共 13 条
[1]   Long-term results of rabbit antithymocyte globulin and basiliximab induction [J].
Brennan, Daniel C. ;
Schnitzler, Mark A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (16) :1736-1738
[2]   Rabbit antithymocyte globulin versus basiliximab in renal transplantation [J].
Brennan, Daniel C. ;
Daller, John A. ;
Lake, Kathleen D. ;
Cibrik, Diane ;
Del Castillo, Domingo .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (19) :1967-1977
[3]   Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody [J].
Kahan, BD ;
Rajagopalan, PR ;
Hall, M .
TRANSPLANTATION, 1999, 67 (02) :276-284
[4]   Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression:: Efficacy and safety [J].
Kyllonen, Lauri E. ;
Eklund, Bjorn H. ;
Pesonen, Eero J. ;
Salmela, Kaija T. .
TRANSPLANTATION, 2007, 84 (01) :75-82
[5]   Randomized double-blind study of immunoprophylaxis with basiliekimab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation [J].
Lawen, JG ;
Davies, EA ;
Mourad, G ;
Oppenheimer, F ;
Molina, MG ;
Rostaing, L ;
Wilkinson, AH ;
Mulloy, LL ;
Bourbigot, BJ ;
Prestele, H ;
Korn, A ;
Girault, D .
TRANSPLANTATION, 2003, 75 (01) :37-43
[6]   Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy [J].
Lebranchu, Y ;
Bridoux, F ;
Büchler, M ;
Le Meur, Y ;
Etienne, I ;
Toupance, O ;
de Ligny, BH ;
Touchard, G ;
Moulin, B ;
Le Pogamp, P ;
Reigneau, O ;
Guignard, M ;
Rifle, G .
AMERICAN JOURNAL OF TRANSPLANTATION, 2002, 2 (01) :48-56
[7]   Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era [J].
Meier-Kriesche, HU ;
Schold, JD ;
Srinivas, TR ;
Kaplan, B .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (03) :378-383
[8]   Sequential protocols using basiliximab versus anti-thymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids [J].
Mourad, G ;
Rostaing, L ;
Legendre, C ;
Garrigue, V ;
Thervet, E ;
Durand, D .
TRANSPLANTATION, 2004, 78 (04) :584-590
[9]   Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients [J].
Nashan, B ;
Moore, R ;
Amlot, P ;
Schmidt, AG ;
Abeywickrama, K ;
Soulillou, JP .
LANCET, 1997, 350 (9086) :1193-1198
[10]   Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients [J].
Noel, Christian ;
Abramowicz, Daniel ;
Durand, Dominique ;
Mourad, Georges ;
Lang, Philippe ;
Kessler, Michele ;
Charpentier, Bernard ;
Touchard, Guy ;
Berthoux, Francois ;
Merville, Pierre ;
Ouali, Nacera ;
Squifflet, Jean-Paul ;
Bayle, Francois ;
Wissing, Karl Martin ;
Hazzan, Marc .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (06) :1385-1392
12